The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Companion Diagnostics Development Services Market, 2020-2030

  • Lowest Price Guaranteed From USD 4,899

  • Published
    January 2020

  • Pages
    350

  • View Count
    4508

Example Insights

Companion Diagnostics Services Market, 2020-2030-Context Companion Diagnostics Services Market, 2020-2030-Service Providers Companion Diagnostics Services Market, 2020-2030-Developed Geographies
Companion Diagnostics Services Market, 2020-2030-Likely Partners Analysis Companion Diagnostics Services Market, 2020-2030-Partnerships & Collaborations Companion Diagnostics Services Market, 2020-2030-Competitveness Analysis
Companion Diagnostics Services Market, 2020-2030-Value chain & Stakeholder Needs Companion Diagnostics Services Market, 2020-2030-Future Forecast Companion Diagnostics Services Market, 2020-2030-Clinical Trial Analysis

 

Overview

Personalized medicine has brought about a paradigm shift within the healthcare sector. However, therapies tailored to specific disease-related molecular signatures require appropriate companion diagnostics in order to make physicians aware of patients’ unique genetic profiles, enabling them to make informed treatment related decisions. In fact, a clinical study of nearly 200 unique pharmacological interventions, which were evaluated across more than 670 clinical trials, suggests that the likelihood of a lead compound passing through various phases of clinical development and eventually getting approved is only 11%. The same study pointed out that using disease-specific biomarker information (indicative of susceptibility to particular types of therapeutics) to recruit patients for clinical research has been associated with a manifold increase in trial success rates. In addition, it is worth noting that companion diagnostics guided drug development efforts have demonstrated to effectively reduce clinical trial costs by almost 60%.  

Given the aforementioned advantages, the industry is gradually shifting from the traditional, one-drug-for-all, paradigm to using tailored pharmacological interventions. This shift is subsequently expected to increase the demand for companion diagnostics. However, given the complexity associated with the co-development of a drug and a corresponding companion diagnostic test, pharmaceutical developers have shown preference to outsource the diagnostics development operations. In fact, nearly 80% of the companies are known to rely on external diagnostics developers for companion diagnostics development, mostly owing to the lack of in-house expertise.  As a result, numerous contract service providers are striving to expand their respective portfolios and developing the capabilities to offer end-to-end services to sponsor companies in this domain. Amidst tough competition, the availability of cutting-edge tools and technologies (such as in situ hybridization (ISH), immunohistochemistry  (IHC), next generation sequencing (NGS), polymerase chain reaction (PCR)) has emerged as a differentiating factor and is likely to grant a competitive advantage to certain service providers over other players in the industry.

Scope of the Report

The “Companion Diagnostics Development Services Market, 2020-2030” report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of diagnostic development services over the next decade. It features an in-depth analysis, highlighting the capabilities of the various stakeholders in this domain. In addition to other elements, the study includes:

  • A detailed assessment of the current market landscape of companies offering companion diagnostics services, including information on the type of services offered, type of analytical technique used and regulatory certifications / accreditations, and other company-specific details (such as year of establishment, company size and geographical location).
  • Tabulated profiles of companion diagnostics service providers (shortlisted on the basis of the number of services offered), featuring an overview of the company, its financial information (if available), and companion diagnostics-related service portfolio details. In addition, each profile includes a list of the likely strategies that may be adopted by these players to support future growth.
  • An analysis of the partnerships and collaborations pertaining to companion diagnostics services from 2017 to 2019, featuring a detailed set of analyses based on various parameters, such as the type of partnership, year of partnership, analytical technique used and the most active players.
  • A list of stakeholders generated based on a detailed analysis of a set of relevant parameters (namely number of clinical trials sponsored by a developer and the time to market for proprietary personalized medicine products), which are anticipated to partner with companion diagnostics services providers in the foreseen future. 
  • A detailed competitiveness analysis of companion diagnostics services providers, taking into consideration the supplier power (based on the year of establishment of developer) and key specifications, such as portfolio strength, type of available technology platform, number of deals signed between 2017-2019.
  • A comparative analysis of the needs of different stakeholders (drug developers, diagnostic developers, testing laboratories, physicians, payers and patients) involved in this domain.
  • A discussion on various steps of the development operations, namely research and development, clinical assessment of the product, manufacturing and assembly, payer negotiation and marketing / sales activities, of a companion diagnostic and the cost requirements across each of the aforementioned stages.
  • An analysis of completed, ongoing and planned clinical trials featuring disease-specific biomarkers. The analysis highlights the key trends associated with these clinical studies across various parameters, such as trial start year, trial status, phase of development, key indications, type of therapy, biomarkers evaluated, enrolled patient population and regional distribution of trials.

One of the key objectives of the report was to estimate the existing market size and the future opportunity for companion diagnostic services providers, over the next decade. Based on multiple parameters, we have provided informed estimates on the evolution of the market for the period 2020-2030. The report also features the likely distribution of the current and forecasted opportunity across [A] key services offered (biomarker discovery, assay development, clinical validation, analytical validation and manufacturing), [B] analytical techniques used (ISH, IHC, NGS, PCR and others), and [C] key geographical regions (North America, Europe, Asia and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.  

The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of discussions held with the following industry stakeholders:

  • Pablo Ortiz (Chief Executive Officer, OWL Metabolomics)
  • Paul Kortschak (Senior Vice President, Novodiax)
  • Lawrence M. Weiss (Chief Scientific Officer, NeoGenomics Laboratories)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the current state of the market for companion diagnostics services, in the short-mid-term and long term.

Chapter 3 is an introductory chapter that highlights the importance of companion diagnostics in relation to personalized medicine. The chapter describes the approaches used to develop a companion diagnostic, along with information on the various analytical techniques that form the basis for such tests. It also provides details on key market drivers and challenges within this industry. 

Chapter 4 provides a list of companion diagnostics services providers. It includes information on the companion diagnostics-related service portfolio (biomarker research / identification, feasibility studies, assay development, analytical validation, clinical validation, regulatory assistance, commercialization, manufacturing and other supporting services), analytical techniques (flow cytometry, in situ hybridization (ISH), immunohistochemistry (IHC), micro array, next generation sequencing (NGS), polymerase chain reaction (PCR), and sanger sequencing), regulatory certification / accreditation, along with the information of service provider year of establishment, company size and geographical location.

Chapter 5 provides tabulated profiles of some of the leading stakeholders in this field (shortlisted on the basis of the strength of product portfolio). Each profile presents a brief overview of the company, financial information (if available) and an informed future outlook.

Chapter 6 features an elaborate analysis and discussion of the various collaborations and partnerships that have been inked amongst players since 2017. It includes a brief description of various types of partnership models that have been adopted by stakeholders in this domain. It also includes a schematic representation that showcases the companies that have established the maximum number of alliances, highlighting key analytical techniques and disease indications. 

Chapter 7 presents the of stakeholders that are anticipated to partner with companion diagnostics services providers in the foreseen future based on a detailed analysis of relevant parameters, namely, number of clinical trials sponsored by a developer and the time to market for proprietary personalized medicine products.

Chapter 8 presents a competitiveness analysis of the companion diagnostics service providers based on supplier power of the developers and portfolio strength. The analysis was designed to enable stakeholder companies to compare their existing capabilities within and beyond their respective peer groups and identify opportunities to achieve a competitive edge in the industry.

Chapter 9 provides information on the needs of different stakeholders (drug developers, diagnostic developers, testing laboratories, physicians, payers and patients) involved in this domain. The chapter qualitatively assesses the various companion diagnostics-related needs of these stakeholders, highlighting their respective perspectives regarding the importance of each need. 

Chapter 10 presents a value chain analysis featuring a discussion on various steps of the development operations, namely R&D development, clinical assessment of the product, manufacturing and assembly, payer negotiation and marketing activities, of a companion diagnostics and the cost requirements across each of the aforementioned stages.

Chapter 11 provides a detailed clinical trial analysis of completed, ongoing and planned studies, related to disease-specific biomarkers, being sponsored by the top pharmaceutical players. The analysis highlights the key trends associated with these clinical studies across various parameters, such as trial start year, trial status, phase of development, key indications, type of therapy, biomarkers evaluated, enrolled patient population and regional distribution of trials

Chapter 12 features a comprehensive market forecast analysis, highlighting the likely growth of companion diagnostics services market till the year 2030. We have provided inputs on the likely distribution of the opportunity based on the services offered (biomarker discovery, feasibility studies, assay development, clinical validation, analytical validation and manufacturing), assay techniques (in situ hybridization (ISH), immune histochemistry (IHC), next generation sequencing (NGS), polymerase chain reaction (PCR) and others), and key geographical regions (North America, Europe, Asia and rest of the world).

Chapter 13 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario. Further, it captures the evolutionary trends that are likely to determine the future of this segment of the companion diagnostics industry.

Chapter 14 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the details of interviews held with Pablo Ortiz (Chief Executive Officer, OWL Metabolomics), Paul Kortschak (Senior Vice President, Novodiax) and Lawrence M. Weiss (Chief Scientific Officer, NeoGenomics Laboratories).

Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 16 is an appendix, which contains a list of companies and organizations mentioned in this report.

Table Of Content

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Evolution of Personalized Medicine

3.3. Overview of Companion Diagnostics
3.3.1. Development of Companion Diagnostics
3.3.2. Analytical Techniques Used in Companion Diagnostic Tests
3.3.2.1. Immunohistochemistry
3.3.2.2. In situ Hybridization
3.3.2.3. Polymerase Chain Reaction
3.3.2.4. DNA Sequencing / Next Generation Sequencing

3.3.3. Advantages of Companion Diagnostics

3.4. Applications of Companion Diagnostics across Different Therapeutic Areas
3.4.1. Oncology
3.4.2. Infectious Diseases
3.4.3. Neurological Disorders

3.5. Regulatory Review and Approval Process for Companion Diagnostics
3.6. Existing Challenges
3.7. Future Roadmap

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Companion Diagnostics Service Providers: Overall Market Landscape
4.2.1 Analysis by Type of Service Offered
4.2.2. Analysis by Type of Analytical Technique
4.2.3. Analysis by Regulatory Accreditation / Certification
4.2.4. Analysis by Type of End User

4.3. Companion Diagnostics Service Providers: Developer Landscape
4.3.1 Analysis by Year of Establishment
4.3.2 Analysis by Company Size
4.3.3 Analysis by Geographical Location
4.3.4 Grid Representation: Analysis by Type of Service Offered, Company Size, and Geographical Location
4.3.5 World Map Representation: Analysis by Geography

5. COMPANY PROFILES
5.1. Chapter Overview

5.2. Key Players in North America
5.2.1. Asuragen
5.2.1.1. Recent Developments and Future Outlook

5.2.2. Covance
5.2.2.1. Recent Developments and Future Outlook

5.2.3. Geneuity
5.2.3.1. Recent Developments and Future Outlook

5.2.4. MD Biosciences
5.2.4.1. Recent Developments and Future Outlook

5.2.5. ResearchDx
5.2.5.1. Recent Developments and Future Outlook

5.3. Players in Europe
5.3.1. Almac Diagnostic Services
5.3.1.1. Recent Developments and Future Outlook

5.3.2. Leica Biosystems
5.3.2.1. Recent Developments and Future Outlook

5.3.3. R-Biopharm
5.3.3.1. Recent Developments and Future Outlook

5.3.4. Tepnel Pharma Services
5.3.4.1. Recent Developments and Future Outlook

5.4. Key Players in Asia-Pacific
5.4.1. BARD1 Life Sciences
5.4.1.1. Recent Developments and Future Outlook

5.4.2. BioMarCare Technologies
5.4.2.1. Recent Developments and Future Outlook

5.4.3. Gencurix
5.4.3.1. Recent Developments and Future Outlook

5.4.4. Macrogen
5.4.4.1. Recent Developments and Future Outlook

6. PARTNERSHIPS AND COLLABORATIONS
6.1 Chapter Overview
6.2 Partnership Models
6.3 List of Partnerships and Collaborations
6.3.1 Analysis by Year of Partnership
6.3.2 Analysis by Type of Partnership
6.3.3 Analysis by Type of Analytical Technique
6.3.4 Analysis by Type of Therapeutic Area
6.3.5 Analysis by Year of Partnership and Type of Partner
6.3.6 Analysis by Type of Partnership and Type of Partner
6.3.7 Most Active Players: Analysis by Number of Partnerships
6.3.8 Popular Analytical Techniques: Analysis by Number of Partnerships
6.3.9 Regional Analysis
6.3.10 Intercontinental and Intracontinental Agreements

7. LIKELY PARTNER ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Scoring Criteria and Key Assumptions
7.4. Likely Partners for Companion Diagnostics Service Providers: Alzheimer’s Disease
7.4.1. Companies Working on the Amyloid Beta Biomarker
7.4.1.1. World Map Representation: Amyloid Beta Biomarker Focused Clinical Trials

7.4.2. Companies Working on the Tau Biomarker
7.4.2.1. World Map Representation: Tau Biomarker Focused Clinical Trials

7.5. Likely Partners for Companion Diagnostics Service Providers: Breast Cancer
7.5.1. Companies Working on the BRCA Biomarker
7.5.1.1. World Map Representation: BRCA Biomarker Focused Clinical Trials

7.5.2. Companies Working on the HER Biomarker
7.5.2.1. World Map Representation: HER Biomarker Focused Clinical Trials

7.5.3. Companies Working on the HR Biomarker
7.5.3.1. World Map Representation: HR Biomarker Focused Clinical Trials

7.5.4. Companies Working on the PD-L1 Biomarker
7.5.4.1. World Map Representation: PD-L1 Biomarker Focused Clinical Trials

7.6. Likely Partners for Companion Diagnostics Service Providers: Colorectal Cancer
7.6.1. Companies Working on the BRAF Biomarker
7.6.1.1. World Map Representation: BRAF Biomarker Focused Clinical Trials

7.6.2. Companies Working on the EGFR Biomarker
7.6.2.1. World Map Representation: EGFR Biomarker Focused Clinical Trials

7.6.3. Companies Working on the KRAS Biomarker
7.6.3.1. World Map Representation: KRAS Biomarker Focused Clinical Trials

7.6.4. Companies Working on the MSI Biomarker
7.6.4.1. World Map Representation: MSI Biomarker Focused Clinical Trials

7.6.5. Companies Working on the NRAS Biomarker
7.6.5.1. World Map Representation: NRAS Biomarker Focused Clinical Trials

7.7. Likely Partners for Companion Diagnostic Service Providers: HIV
7.7.1. Companies Working on the CCR5 Biomarker
7.7.1.1. World Map Representation: CCR5 Biomarker Focused Clinical Trials

7.8. Likely Partners for Companion Diagnostics Service Providers: Lung Cancer
7.8.1. Companies Working on the ALK Biomarker
7.8.1.1. World Map Representation: ALK Biomarker Focused Clinical Trials

7.8.2. Companies Working on the EGFR Biomarker
7.8.2.1. World Map Representation: EGFR Biomarker Focused Clinical Trials

7.8.3. Companies Working on the PD-L1 Biomarker
7.8.3.1. World Map Representation: PD-L1 Biomarker Focused Clinical Trials

7.8.4. Companies Working on the ROS Biomarker
7.8.4.1. World Map Representation: ROS Biomarker Focused Clinical Trials

7.9. Likely Partners for Companion Diagnostics Service Providers: NASH / NAFLD
7.9.1. Companies Working on the AST Biomarker
7.9.1.1. World Map Representation: AST Biomarker Focused Clinical Trials

7.10. Likely Partners for Companion Diagnostics Service Providers: Ovarian Cancer
7.10.1. Companies Working on the BRCA Biomarker
7.10.1.1. World Map Representation: BRCA Biomarker Focused Clinical Trials

7.10.2. Companies Working on the CA-125 Biomarker
7.10.2.1. World Map Representation: CA-125 Biomarker Focused Clinical Trials

7.11. Likely Partners for Companion Diagnostics Service Providers: Prostate Cancer
7.11.1. Companies Working on the PTEN Biomarker
7.11.1.1. World Map Representation: PTEN Biomarker Focused Clinical Trials

8. COMPANY COMPETITIVENESS ANALYSIS
8.1 Chapter Overview
8.2 Methodology
8.3 Assumptions and Key Parameters
8.4 Company Competitiveness Analysis
8.4.1 Companion Diagnostics Service Providers based in North America
8.4.2 Companion Diagnostics Service Providers based in Europe
8.4.3 Companion Diagnostics Service Providers based in Asia Pacific / RoW

9. STAKEHOLDER NEEDS ANALYSIS 
9.1. Chapter Overview 
9.2. Companion Diagnostics: Needs of Different Stakeholders 
9.3. Comparison of Needs of Various Stakeholders 
9.3.1. Needs of Drug Developers 
9.3.2. Needs of Companion Diagnostics Developers 
9.3.3. Needs of Regulatory Authorities 
9.3.4. Needs of Testing Laboratories 
9.3.5. Needs of Payers / Insurance Providers 
9.3.6. Needs of Physicians 
9.3.7. Needs of Patients 

10. VALUE CHAIN ANALYSIS 
10.1. Chapter Overview 
10.2. Companion Diagnostics Value Chain: Cost Distribution 
10.2.1. Research and Product Development 
10.2.2. Manufacturing and Assembly 
10.2.3. Clinical Trials, FDA Approval and Other Administrative Tasks 
10.2.4. Payer Negotiation and KOL Engagement 
10.2.5. Marketing and Sales 

10.3. Companion Diagnostics Development Operations: Key Cost Contributors 
10.4. Companion Diagnostics Co-Development Operations: Key Cost Contributors 

11. CLINICAL RESEARCH ON CANCER BIOMARKERS: BIG PHARMA PERSPECTIVE 
11.1. Chapter Overview 
11.2. Methodology 
11.3. Clinical Trial Analysis 
11.3.1. List of Likely Drug Candidates for IVD Developers 

11.4. Cumulative Distribution of Biomarker Focused Trials by Registration Year, 2016-2019 
11.4.1. Analysis of Trials for Most Popular Biomarkers 
11.4.2. Analysis of Trials for Moderately Popular Biomarkers 
11.4.3. Analysis of Trials for Less Popular / Preliminary Stage Biomarkers 
11.4.4. Other Emerging Biomarkers: Word Cloud 
11.4.5. Cumulative Distribution of Trials of the Most Popular Biomarkers by Registration Year 
11.4.6. Cumulative Distribution of Trials of the Moderately Popular Biomarkers by Registration Year 
11.4.7. Cumulative Distribution of Trials of the Less Popular Biomarkers by Registration Year 

11.5. Analysis of Biomarker Focused Trials for Most Popular Indications 
11.5.1. Analysis of Trials for Moderately Popular Indications 
11.5.2. Analysis of Trials for Less Popular and Other Indications 
11.5.3. Other Emerging Indications: Word Cloud 
11.5.4. Cumulative Distribution of Trials of the Most Popular Indications by Registration Year 
11.5.5. Cumulative Distribution of Trials of the Moderately Popular Indications by Registration Year 
11.5.6. Cumulative Distribution of Trials of the Less Popular / Preliminary Stage Indications by Registration Year 

11.6. Analysis of Biomarker Focused Trials by Phase of Development 
11.6.1. Analysis of Trials of the Most Popular Biomarkers 
11.6.2. Analysis of Trials of the Moderately Popular Biomarkers 
11.6.3. Analysis of Trials of the Less Popular and Other Biomarkers 
11.6.4. Analysis of Trials of the Most Popular Indications 
11.6.5. Analysis of Trials of the Moderately Popular Indications 
11.6.6. Analysis of Trials of the Less Popular and Other Indications 

11.7. Analysis of Biomarker Focused Trials by Sponsor 
11.7.1. Analysis of Trials of the Most Popular Biomarkers 
11.7.2. Analysis of Trials of the Moderately Popular Biomarkers 
11.7.3. Analysis of Trials of the Most Popular Indications 
11.7.4. Analysis of Trials of the Moderately Popular Indications 

11.8. Analysis of Biomarker Focused Trials by Recruitment Status 
11.9. Analysis of Biomarker Focused Trials by Therapy Design 

11.10. Analysis of Biomarker Focused Trials by Geography 
11.10.1. Analysis of Trials by Phase of Development and Recruitment Status 

11.11. Clinical Trials Summary: Analysis of Biomarker Focused Trials by Most Popular Indications 
11.12. Clinical Trials Summary: Analysis of Biomarker Focused Trials by Moderately Popular Indications 
11.13. Clinical Trials Summary: Analysis of Biomarker Focused Trials by Preliminary Stage Indications 

12. MARKET FORECAST AND OPPORTUNITY ANALYSIS 
12.1. Chapter Overview
12.2. Key Assumptions and Forecast Methodology

12.3. Global Companion Diagnostics Services Market, 2020-2030
12.3.1. Global Companion Diagnostics Services Market: Distribution by Type of Service Offered, 2020-2030
12.3.2. Global Companion Diagnostics Services Market: Distribution by Type of Analytical Technique, 2020-2030
12.3.3. Global Companion Diagnostics Services Market: Distribution by Region, 2020-2030

12.4. Companion Diagnostics Services Market in the North America, 2020-2030
12.4.1. Companion Diagnostics Services Market in the North America: Distribution by Type of Service Offered, 2020-2030
12.4.2. Companion Diagnostics Services Market in the North America: Distribution by Type of Analytical Technique, 2020-2030

12.5. Companion Diagnostics Services Market in Europe, 2020-2030
12.5.1. Companion Diagnostics Services Market in Europe: Distribution by Type of Service Offered, 2020-2030
12.5.2. Companion Diagnostics Services Market in Europe: Distribution by Type of Analytical Technique, 2020-2030

12.6. Companion Diagnostics Services Market in Asia, 2020-2030
12.6.1. Companion Diagnostics Services Market in Asia: Distribution by Type of Service Offered, 2020-2030
12.6.2. Companion Diagnostics Services Market in Asia: Distribution by Type of Analytical Technique, 2020-2030

12.7. Companion Diagnostics Services Market in Rest of the World, 2020-2030
12.7.1. Companion Diagnostics Services Market in Rest of the World: Distribution by Type of Service Offered, 2020-2030
12.7.2. Companion Diagnostics Services Market in Rest of the World: Distribution by Type of Analytical Technique, 2020-2030

13. EXECUTIVE INSIGHTS
13.1. Chapter Overview

13.2. OWL Metabolomics
13.2.1. Company Snapshot
13.2.2. Interview Transcript: Pablo Ortiz, Chief Executive Officer

13.3. Novodiax
13.3.1 Company Snapshot
13.3.2. Interview Transcript: Paul Kortschak, Senior Vice President

14. CONCLUDING REMARKS

15. APPENDIX 1: TABULATED DATA

16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

Figure 3.1 Evolution of Personalized Medicine, 2012-2017
Figure 3.2 Preclinical Development of Biomarker-based Targeted Therapies
Figure 3.3 Role of Companion Diagnostics in Clinical Trials
Figure 3.4 Companion Diagnostics: Key Advantages
Figure 3.5 Companion Diagnostics: Primary Development-related Challenges
Figure 3.6 Companion Diagnostics: Market Drivers and Constraints
Figure 4.1 Companion Diagnostics Service Providers: Distribution by Type of Service Offered
Figure 4.2 Companion Diagnostics Service Providers: Distribution by Type of Analytical Technique
Figure 4.3 Companion Diagnostics Service Providers: Distribution by Type of Regulatory Accreditation / Certification
Figure 4.4 Companion Diagnostics Service Providers: Distribution by Type of End User
Figure 4.5 Companion Diagnostics Service Providers: Distribution by Year of Establishment
Figure 4.6 Companion Diagnostics Service Providers: Distribution by Company Size
Figure 4.7 Companion Diagnostics Service Providers: Distribution by Geographical Location
Figure 4.8 Grid Representation: Distribution by Type of Service Offered, Company Size, and Geographical Location
Figure 4.9 World Map Representation: Analysis by Geography
Figure 6.1. Partnerships and Collaborations: Cumulative Year-wise Trend, 2017-2019
Figure 6.2. Partnerships and Collaborations: Distribution by Type of Partnership
Figure 6.3. Partnerships and Collaborations: Year-wise Trend by Type of Partnership 2017-2019.
Figure 6.4. Partnerships and Collaborations: Distribution by Type of Analytical Technique and Type of Partnership
Figure 6.5. Partnerships and Collaborations: Distribution by Type of Therapeutic Area and Type of Partnership
Figure 6.6. Partnerships and Collaborations: Year-wise Trend for Type of Partner
Figure 6.7. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 6.8. Most Active Players: Distribution by Number of Partnerships
Figure 6.9. Partnership and Collaborations: Regional Distribution
Figure 6.10. Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Figure 7.1. World Map Representation: Distribution of Amyloid Beta Biomarker Focused Clinical Trials
Figure 7.2. World Map Representation: Distribution of Tau Biomarker Focused Clinical Trials
Figure 7.3. World Map Representation: Distribution of BRCA Focused Clinical Trials
Figure 7.4. World Map Representation: Distribution of HER Focused Clinical Trials
Figure 7.5. World Map Representation: Distribution of HR Focused Clinical Trials
Figure 7.6. World Map Representation: Distribution of PD-L1 Focused Clinical Trials
Figure 7.7. World Map Representation: Distribution of BRAF Focused Clinical Trials
Figure 7.8. World Map Representation: Distribution of EGFR Focused Clinical Trials
Figure 7.9. World Map Representation: Distribution of KRAS Focused Clinical Trials
Figure 7.10. World Map Representation: Distribution of MSI Focused Clinical Trials
Figure 7.11. World Map Representation: Distribution of NRAS Focused Clinical Trials
Figure 7.12. World Map Representation: Distribution of CCR5 Focused Clinical Trials
Figure 7.13. World Map Representation: Distribution of ALK Focused Clinical Trials
Figure 7.14. World Map Representation: Distribution of EGFR Focused Clinical Trials
Figure 7.15. World Map Representation: Distribution of PD-L1 Focused Clinical Trials
Figure 7.16. World Map Representation: Distribution of ROS Focused Clinical Trials
Figure 7.17. World Map Representation: Distribution of AST Focused Clinical Trials
Figure 7.18. World Map Representation: Distribution of BRCA Focused Clinical Trials
Figure 7.19. World Map Representation: Distribution of CA-125 Focused Clinical Trials
Figure 7.20. World Map Representation: Distribution of PTEN Focused Clinical Trials
Figure 8.1. Competitiveness Analysis: Companion Diagnostics Service Providers Based in North America
Figure 8.2. Competitiveness Analysis: Companion Diagnostics Service Providers Based in Europe
Figure 8.3. Competitiveness Analysis: Companion Diagnostics Service Providers Based in Asia Pacific / RoW
Figure 9.1. Stakeholder Needs Analysis: Comparison of Needs of Different Stakeholders
Figure 9.2. Stakeholder Needs Analysis: Comparison of Needs of Various Stakeholders Stakeholder Needs Analysis: Comparison of Needs of Various Stakeholders
Figure 9.3. Stakeholder Needs Analysis: Comparison of Needs of Companion Diagnostics Stakeholder Needs Analysis: Comparison of Needs of Companion Diagnostics Developers
Figure 9.4. Stakeholder Needs Analysis: Needs of Regulatory Authorities
Figure 9.5. Stakeholder Needs Analysis: Needs of Testing Laboratories
Figure 9.6. Stakeholder Needs Analysis: Needs of Payers / Insurance Providers
Figure 9.7. Stakeholder Needs Analysis: Needs of Physicians
Figure 9.8. Stakeholder Needs Analysis: Needs of Patients
Figure 10.1 Companion Diagnostics Value Chain: Cost Distribution
Figure 10.2 Companion Diagnostics Value Chain: Research and Product Development
Figure 10.3 Companion Diagnostics Value Chain: Manufacturing and Assembly
Figure 10.4 Companion Diagnostics Value Chain: Clinical Trials, FDA Approval and Other Administrative Tasks
Figure 10.5 Companion Diagnostics Value Chain: Payer Negotiation and KOL Engagement
Figure 10.6 Companion Diagnostics Value Chain: Marketing and Sales
Figure 10.7 Companion Diagnostics Development Operations: Key Cost Contributors
Figure 10.8 Companion Diagnostics Co-Development Operations: Key Cost Contributors
Figure 11.1 Clinical Trial Analysis: Distribution by Trial Registration Year
Figure 11.2 Clinical Trial Analysis: Distribution of Trials of the Most Popular Biomarkers by Trial Registration Year
Figure 11.3 Clinical Trial Analysis: Distribution of Trials of the Moderately Popular Biomarkers by Trials Registration Year
Figure 11.4 Clinical Trial Analysis: Distribution of Trials of the Less Popular / Preliminary Stage Biomarkers by Trial Registration Year
Figure 11.5 Other Emerging Biomarkers: Word Cloud
Figure 11.6 Clinical Trial Analysis: Distribution of Trials of the Most Popular Biomarkers by Trial Registration Year
Figure 11.7 Clinical Trial Analysis: Distribution of Trials of the Moderately Popular Biomarkers by Trial Registration Year
Figure 11.8 Clinical Trial Analysis: Distribution of Trials of the Less Popular and Other Biomarkers by Trial Registration Year
Figure 11.9 Clinical Trial Analysis: Distribution by Most Popular Indications
Figure 11.10 Clinical Trial Analysis: Distribution of Trials of the Moderately Popular Indications
Figure 11.11 Clinical Trial Analysis: Distribution of Trials of the Less Popular and Other Indications
Figure 11.12 Less Popular and Other Indications: Word Cloud
Figure 11.13 Clinical Trial Analysis: Distribution of Trial of the Most Popular Indications by Trial Registration Year
Figure 11.15 Clinical Trial Analysis: Distribution of Trial of the Moderately Popular Indications by Trial Registration Year
Figure 11.16 Clinical Trial Analysis: Distribution of Trial of the Less Popular and Other Indications by Trial Registration Year
Figure 11.17 Clinical Trial Analysis: Distribution by Trial Phase of Development
Figure 11.18 Clinical Trial Analysis: Distribution of Trials of the Most Popular Biomarkers by Phase of Development
Figure 11.19 Clinical Trial Analysis: Distribution of Trials of the Moderately Popular Biomarkers by Phase of Development
Figure 11.20 Clinical Trial Analysis: Distribution of Trials of the Less Popular and Other Biomarkers by Phase of Development
Figure 11.21 Clinical Trial Analysis: Distribution of Trials of the Most Popular Indications by Phase of Development
Figure 11.22 Clinical Trial Analysis: Distribution of Trials of the Moderately Popular Indications by Phase of Development
Figure 11.23 Clinical Trial Analysis: Distribution of Trials of the Less Popular / Emerging Indications by Phase of Development
Figure 11.24 Clinical Trial Analysis: Distribution of Trials by Sponsor
Figure 11.25 Clinical Trial Analysis: Distribution of Trials of the Most Popular Biomarkers by Sponsor
Figure 11.26 Clinical Trial Analysis: Distribution of Trials of the Moderately Popular Biomarkers by Sponsor
Figure 11.27 Clinical Trial Analysis: Distribution of Trials of the Most Popular Indications by Sponsor
Figure 11.28 Clinical Trial Analysis: Distribution of Trials of the Moderately Popular Indications by Sponsor
Figure 11.29 Clinical Trial Analysis: Distribution by Recruitment Status
Figure 11.30 Clinical Trial Analysis: Distribution by Therapy Design
Figure 11.31 Clinical Trial Analysis: Distribution by Geography
Figure 11.32 Clinical Trial Analysis: Distribution by Enrolled Patient Population
Figure 11.33 Clinical Trial Analysis: Distribution of Trials of the Lung Cancer by Affiliated Biomarkers
Figure 11.34 Clinical Trial Analysis: Distribution of Trials of the Breast Cancer by Affiliated Biomarkers
Figure 11.35 Clinical Trial Analysis: Distribution of Trials of the Lymphoma by Affiliated Biomarkers
Figure 11.36 Clinical Trial Analysis: Distribution of Trials of the Ovarian Cancer by Affiliated Biomarkers
Figure 11.37 Clinical Trial Analysis: Distribution of Trials of the Prostate Cancer by Affiliated Biomarkers
Figure 11.38 Clinical Trial Analysis: Distribution of Trials of the Melanoma by Affiliated Biomarkers
Figure 11.39 Clinical Trial Analysis: Distribution of Trials of the Colon / Colorectal Cancer by Affiliated Biomarkers
Figure 11.40 Clinical Trial Analysis: Distribution of Trials of the Head and Neck Cancer by Affiliated Biomarkers
Figure 12.1. Global Companion Diagnostics Services Market, 2020-2030 (USD Billion)
Figure 12.2. Global Companion Diagnostics Services Market: Distribution by Type of Service Offered, 2020-2030 (USD Billion)
Figure 12.3. Global Companion Diagnostics Services Market: Distribution by Type of Analytical Technique, 2020-2030 (USD Billion)
Figure 12.4. Global Companion Diagnostics Services Market: Distribution by Region, 2020-2030 (USD Billion)
Figure 12.5. Companion Diagnostics Services Market in the North America, 2020-2030 (USD Billion)
Figure 12.6. Companion Diagnostics Services Market in the North America: Distribution by Type of Service Offered, 2020-2030 (USD Billion)
Figure 12.7. Companion Diagnostics Services Market in the North America: Distribution by Type of Analytical Technique, 2020-2030 (USD Billion)
Figure 12.8. Companion Diagnostics Services Market in Europe, 2020-2030 (USD Billion)
Figure 12.9. Companion Diagnostics Services Market in Europe: Distribution by Type of Service Offered, 2020-2030 (USD Billion)
Figure 12.10. Companion Diagnostics Services Market in Europe: Distribution by Type of Analytical Technique, 2020-2030 (USD Billion)
Figure 12.11. Companion Diagnostics Services Market in Asia, 2020-2030 (USD Billion)
Figure 12.12. Companion Diagnostics Services Market in Asia: Distribution by Type of Service Offered, 2020-2030 (USD Billion)
Figure 12.13. Companion Diagnostics Services Market in Asia: Distribution by Type of Analytical Technique, 2020-2030 (USD Billion)
Figure 12.14. Companion Diagnostics Services Market in Rest of the World, 2020-2030 (USD Billion)
Figure 12.15. Companion Diagnostics Services Market in Rest of the World: Distribution by Type of Service Offered, 2020-2030 (USD Billion)
Figure 12.16. Companion Diagnostics Services Market in Rest of the World: Distribution by Type of Analytical Technique, 2020-2030

List of Tables

Table 4.1 Companion Diagnostics Service Providers: Information on Type of Service Offered
Table 4.2 Companion Diagnostics Service Providers: Information on Type of Analytical Techniques
Table 4.3 Companion Diagnostics Service Providers: Additional Information (Regulatory Certification / Accreditation and Type of End User)
Table 5.1 Companion Diagnostic Service Providers: List of Profiled Companies
Table 5.2 Asuragen: Company Snapshot
Table 5.3 Asuragen: Recent Developments and Future Outlook
Table 5.4 Covance: Company Snapshot
Table 5.5 Covance: Recent Developments and Future Outlook
Table 5.6 Geneuity: Company Snapshot
Table 5.7 Geneuity: Recent Developments and Future Outlook
Table 5.8 MD BIOSCIENCES: Company Snapshot
Table 5.9 MD BIOSCIENCES: Recent Developments and Future Outlook
Table 5.10 ResearchDx: Company Snapshot
Table 5.11 ResearchDx: Recent Developments and Future Outlook
Table 5.12 Almac Diagnostic Services: Company Snapshot
Table 5.13 Almac Diagnostic Services: Recent Developments and Future Outlook
Table 5.14 Leica Biosystems: Company Snapshot
Table 5.15 Leica Biosystems: Recent Developments and Future Outlook
Table 5.16 R-Biopharm: Company Snapshot
Table 5.17 R-Biopharm: Recent Developments and Future Outlook
Table 5.18 Tepnel Pharma Services: Company Snapshot
Table 5.19 Tepnel Pharma Services: Recent Developments and Future Outlook
Table 5.20 BARD1 Life Sciences: Company Snapshot
Table 5.21 BARD1 Life Sciences: Recent Developments and Future Outlook
Table 5.22 BioMarCare: Company Snapshot
Table 5.23 BioMarCare Technologies: Recent Developments and Future Outlook
Table 5.24 Gencurix: Company Snapshot
Table 5.25 Gencurix: Recent Developments and Future Outlook
Table 5.26 Macrogen: Company Snapshot
Table 5.27 Macrogen: Recent Developments and Future Outlook
Table 6.1 Companion Diagnostic Service Providers: Partnerships and Collaborations, 2014-2019
Table 7.1 Companies Working on the Amyloid Beta Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 7.2 Companies Working on the Tau Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 7.3 Companies Working on the BRCA Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 7.4 Companies Working on the HER Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 7.5 Companies Working on the HR Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 7.6 Companies Working on the PD-L1 Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 7.7 Companies Working on the BRAF Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 7.8 Companies Working on the EGFR Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 7.9 Companies Working on the KRAS Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 7.10 Companies Working on the MSI Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 7.11 Companies Working on the NRAS Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 7.12 Companies Working on the CCR5 Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 7.13 Companies Working on the ALK Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 7.14 Companies Working on the EGFR Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 7.15 Companies Working on the PD-L1 Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 7.16 Companies Working on the RET Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 7.17 Companies Working on the ROS Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 7.18 Companies Working on the AST Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 7.19 Companies Working on the BRCA Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 7.20 Companies Working on the CA-125 Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 7.21 Companies Working on the PTEN Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 11.1 List of Likely Drug Candidates / Potential Collaborators for Diagnostic Developers
Table 11.2 List of Biomarkers across Moderately Popular Indications
Table 11.3 List of Biomarkers across Emerging Indications
Table 16.1. Companion Diagnostics Service Providers: Distribution by Type of Service Offered
Table 16.2. Companion Diagnostics Service Providers: Distribution by Type of Analytical Technique
Table 16.3. Companion Diagnostics Service Providers: Distribution by Type of Regulatory Accreditation / Certification
Table 16.4. Companion Diagnostics Service Providers: Distribution by Type of End User
Table 16.5. Companion Diagnostics Service Providers: Distribution by Year of Establishment
Table 16.6. Companion Diagnostics Service Providers: Distribution by Company Size
Table 16.7. Companion Diagnostics Service Providers: Distribution by Geographical Location
Table 16.8. Partnerships and Collaborations: Cumulative Year-wise Trend, 2017-2019
Table 16.9. Partnerships and Collaborations: Distribution by Type of Partnership
Table 16.10. Partnerships and Collaborations: Year-wise Trend by Type of Partnership 2017-2019.
Table 16.11. Partnerships and Collaborations: Distribution by Type of Analytical Technique and Type of Partnership
Table 16.12. Partnerships and Collaborations: Distribution by Type of Therapeutic Area and Type of Partnership
Table 16.13. Partnerships and Collaborations: Year-wise Trend for Type of Partner
Table 16.14. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table 16.15. Most Active Players: Distribution by Number of Partnerships
Table 16.16. Partnership and Collaborations: Regional Distribution
Table 16.17. Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Table 16.18. Companion Diagnostics Value Chain: Cost Distribution
Table 16.19. Clinical Trial Analysis: Distribution by Trial Registration Year
Table 16.20. Clinical Trial Analysis: Distribution of Trials of the Most Popular Biomarkers by Trial Registration Year
Table 16.21. Clinical Trial Analysis: Distribution of Trials of the Moderately Popular Biomarkers by Trials Registration Year
Table 16.22. Clinical Trial Analysis: Distribution of Trials of the Less Popular / Preliminary Stage Biomarkers by Trial Registration Year
Table 16.23. Clinical Trial Analysis: Distribution of Trials of the Most Popular Biomarkers by Trial Registration Year
Table 16.24. Clinical Trial Analysis: Distribution of Trials of the Moderately Popular Biomarkers by Trial Registration Year
Table 16.25. Clinical Trial Analysis: Distribution of Trials of the Less Popular and Other Biomarkers by Trial Registration Year
Table 16.26. Clinical Trial Analysis: Distribution by Most Popular Indications
Table 16.27. Clinical Trial Analysis: Distribution of Trials of the Moderately Popular Indications
Table 16.28. Clinical Trial Analysis: Distribution of Trials of the Less Popular and Other Indications
Table 16.29. Clinical Trial Analysis: Distribution of Trial of the Most Popular Indications by Trial Registration Year
Table 16.30. Clinical Trial Analysis: Distribution of Trial of the Moderately Popular Indications by Trial Registration Year
Table 16.31. Clinical Trial Analysis: Distribution of Trial of the Less Popular and Other Indications by Trial Registration Year
Table 16.32. Clinical Trial Analysis: Distribution by Trial Phase of Development
Table 16.33. Clinical Trial Analysis: Distribution of Trials of the Most Popular Biomarkers by Phase of Development
Table 16.34. Clinical Trial Analysis: Distribution of Trials of the Moderately Popular Biomarkers by Phase of Development
Table 16.35. Clinical Trial Analysis: Distribution of Trials of the Less Popular and Other Biomarkers by Phase of Development
Table 16.36. Clinical Trial Analysis: Distribution of Trials of the Most Popular Indications by Phase of Development
Table 16.37. Clinical Trial Analysis: Distribution of Trials of the Moderately Popular Indications by Phase of Development
Table 16.38. Clinical Trial Analysis: Distribution of Trials of the Less Popular / Emerging Indications by Phase of Development
Table 16.39. Clinical Trial Analysis: Distribution of Trials by Sponsor
Table 16.40. Clinical Trial Analysis: Distribution of Trials of the Most Popular Biomarkers by Sponsor
Table 16.41. Clinical Trial Analysis: Distribution of Trials of the Moderately Popular Biomarkers by Sponsor
Table 16.42. Clinical Trial Analysis: Distribution of Trials of the Most Popular Indications by Sponsor
Table 16.43. Clinical Trial Analysis: Distribution of Trials of the Moderately Popular Indications by Sponsor
Table 16.44. Clinical Trial Analysis: Distribution by Recruitment Status
Table 16.45. Clinical Trial Analysis: Distribution by Therapy Design
Table 16.46. Global Companion Diagnostics Services Market, Base, Optimistic and Conservative Scenario, 2020-2030 (USD Billion)
Table 16.47. Global Companion Diagnostics Services Market, Base, Optimistic and Conservative Scenario: Distribution by Type of Service Offered, 2020-2030 (USD Billion)
Table 16.48. Global Companion Diagnostics Services Market, Base, Optimistic and Conservative Scenario: Distribution by Type of Analytical Technique, 2020-2030 (USD Billion)
Table 16.49. Global Companion Diagnostics Services Market, Base, Optimistic and Conservative Scenario: Distribution by Region, 2020-2030 (USD Billion)
Table 16.50. Companion Diagnostics Services Market in the North America, Base, Optimistic and Conservative Scenario, 2020-2030 (USD Billion)
Table 16.51. Companion Diagnostics Services Market in the North America: Distribution by Type of Service Offered, 2020-2030 (USD Billion)
Table 16.52. Companion Diagnostics Services Market in the North America: Distribution by Type of Analytical Technique, 2020-2030 (USD Billion)
Table 16.53. Companion Diagnostics Services Market in Europe, Base, Optimistic and Conservative Scenario, 2020-2030 (USD Billion)
Table 16.54. Companion Diagnostics Services Market in Europe: Distribution by Type of Service Offered, 2020-2030 (USD Billion)
Table 16.55. Companion Diagnostics Services Market in Europe: Distribution by Type of Analytical Technique, 2020-2030 (USD Billion)
Table 16.56. Companion Diagnostics Services Market in Asia, Base, Optimistic and Conservative Scenario, 2020-2030 (USD Billion)
Table 16.57. Companion Diagnostics Services Market in Asia: Distribution by Type of Service Offered, 2020-2030 (USD Billion)
Table 16.58. Companion Diagnostics Services Market in Asia: Distribution by Type of Analytical Technique, 2020-2030 (USD Billion)
Table 16.59. Companion Diagnostics Services Market in Rest of the World, Base, Optimistic and Conservative Scenario, 2020-2030 (USD Billion)
Table 16.60. Companion Diagnostics Services Market in Rest of the World: Distribution by Type of Service Offered, 2020-2030 (USD Billion)
Table 16.61. Companion Diagnostics Services Market in Rest of the World: Distribution by Type of Analytical Technique, 2020-2030 (USD Billion)

Listed Companies

  1. 20/20 GeneSystems
  2. A&G Pharmaceutical
  3. A4PBio
  4. Abbott
  5. AbbVie
  6. Abcam
  7. Abnova
  8. AccuGenomics
  9. Acobiom
  10. ACT Genomics
  11. Active Motif
  12. AdeptBio
  13. Adial Pharmaceuticals
  14. Admera Health
  15. Advanced Cell Diagnostics
  16. Agena Bioscience
  17. Agendia
  18. Agilent Technologies
  19. Agiomix
  20. Agios Pharmaceuticals
  21. AgriGenome Labs
  22. AKESOgen
  23. Akoya Biosciences
  24. Almac Diagnostic Services
  25. AltheaDx
  26. Amgen
  27. Amoy Diagnostics
  28. ANGLE
  29. Annoroad Gene Technology
  30. Applied BioCode
  31. ARCA Biopharma
  32. ArcherDX
  33. Array BioPharma
  34. ARUP Laboratories
  35. Ascenda Biosciences
  36. Aspira Pathlab and Diagnostics
  37. Astellas Pharma
  38. AstraZeneca
  39. Asuragen
  40. AurKa Pharma
  41. Avant Diagnostics
  42. Ayala Pharmaceuticals
  43. BARD1 Life Sciences
  44. Bayer
  45. Beaufort Services
  46. Beckman Coulter
  47. BeiGene
  48. BGI Genomics
  49. Biocartis
  50. Biocept
  51. BioChain
  52. Biocrates Life Sciences
  53. Biodesix
  54. BioFire Diagnostics
  55. BioFluidica
  56. BioGenex
  57. BioIVT
  58. Biolidics
  59. BioMarCare Technologies
  60. BioMarker Strategies
  61. Biomarker Technologies
  62. bioMérieux 
  63. Biotron Healthcare
  64. BioVendor
  65. Bliss Biopharmaceutical
  66. Blueprint Medicines
  67. Bosch Healthcare Solutions
  68. Bristol-Myers Squibb
  69. Brooks Automation
  70. CANbridge Life Sciences
  71. Cancer Genetics
  72. Cancer Treatment Centers of America
  73. CancerGuide Diagnostics
  74. Caprion Biosciences
  75. Caris Life Sciences
  76. CD Genomics
  77. CeGaT
  78. Celgene
  79. Celldex Therapeutics
  80. Cellestis
  81. CENTOGENE
  82. Chipscreen Biosciences
  83. Chronix Biomedical
  84. CIRCULOGENE
  85. Clarient
  86. Clinical Genomics
  87. Clinical Reference Laboratory
  88. Clovis Oncology
  89. Co-Diagnostics
  90. Companion Diagnostics Network
  91. ConquerX
  92. CORE Diagnostics
  93. Corgenix
  94. Covance
  95. Creative Biolabs
  96. Curidium Medica
  97. Cypher Genomics
  98. Cyprotex
  99. Daiichi Sankyo
  100. Debiopharm Group
  101. deCODE genetics
  102. Definiens
  103. Delee
  104. DiaCarta
  105. Diaceutics
  106. DiaDx
  107. Diversigen
  108. DNAnexus
  109. DRG International
  110. Drug Response Dx
  111. Eisai
  112. EKF Diagnostics
  113. Eli Lilly and Company
  114. Elypta
  115. EMD Serono
  116. Empire Genomics
  117. Enzo Biochem
  118. Eone-Diagnomics Genome Center
  119. Epigenomics
  120. Epizyme
  121. Eurofins
  122. European Network for Gynaecological Oncological Trial groups (ENGOT)
  123. European Organization for the Research and Treatment of Cancer
  124. Ex5 Genomics
  125. Exagen
  126. Excilone
  127. ExonHit Therapeutics
  128. Exosome Diagnostics
  129. Five Prime Therapeutics
  130. Flagship Biosciences
  131. Foundation Medicine
  132. Freenome
  133. Gencurix
  134. GeneCast Biotechnology
  135. GeneCentric Therapeutics 
  136. Genentech
  137. General Biologicals 
  138. Geneseq Biosciences
  139. Geneuity
  140. GENEWIZ
  141. GENFIT
  142. Genomictree
  143. Genoptix
  144. Genosity
  145. Genostics
  146. GLAS
  147. GOG Foundation
  148. Guangzhou Wondfo Biotech
  149. Guangzhou Kingmed Diagnostics Group
  150. Guardant Health
  151. HalioDx
  152. Halozyme Therapeutics
  153. Hangzhou Normal University
  154. Watson Biotech
  155. Hematogenix
  156. HistoGeneX
  157. HistologiX
  158. Hologic
  159. Horizon Discovery
  160. HTG Molecular Diagnostics
  161. Hummingbird Diagnostics
  162. Hutchison MediPharma
  163. ICON
  164. IDbyDNA
  165. Illumina
  166. ImaginAb
  167. ImmusanT
  168. IncellDx
  169. Incyte
  170. Inotrem
  171. Inovio Pharmaceuticals
  172. Insight Genetics
  173. Inspirata
  174. IntegraGen
  175. Intelligent OMICS
  176. Interpace Biosciences
  177. Invivoscribe
  178. IQVIA
  179. Janssen Biotech
  180. Keen Eye
  181. Lab21
  182. LabCorp
  183. LC Sciences
  184. Leica Biosystems
  185. Lineagen
  186. Lipomics Technologies
  187. Locus Biosciences
  188. Loxo Oncology
  189. Lucence Diagnostics
  190. Luminex
  191. LungLife AI
  192. Macrogen
  193. MacroGenics
  194. MD Biosciences
  195. MDNA Life Sciences
  196. MDxHealth
  197. MedCDx
  198. MedGenome
  199. Medical & Biological Laboratories
  200. Medivation
  201. MEDx (Suzhou) Translational Medicine
  202. Memorial Sloan Kettering Cancer Center
  203. Menarini Silicon Biosystems
  204. Merck
  205. Metanomics Health
  206. MetaStat
  207. Mission Bio
  208. MolecularMD
  209. Mount Sinai Health System
  210. multimmune
  211. Myriad Genetic
  212. NAMSA
  213. NanoString Technologies
  214. Natera
  215. Navigate BioPharma
  216. NEO New Oncology
  217. NeoGenomics
  218. Nodality
  219. N-of-One
  220. Novartis Pharmaceuticals
  221. Novodiax
  222. Novogene
  223. NSABP Foundation
  224. NuvOx Pharma
  225. Ocean Ridge Biosciences
  226. OmniSeq
  227. Oncimmune 
  228. Onyx Pharmaceuticals
  229. OPKO Health
  230. Orbit Genomics
  231. Osmetech
  232. OWL Metabolomics
  233. Oxford BioTherapeutics
  234. PamGene International
  235. Panacea Pharma
  236. PANAGENE
  237. Pangaea Oncology
  238. Paragon Genomics
  239. ParagonDx
  240. PAREXEL
  241. ParkwayHealth Laboratory
  242. PerkinElmer
  243. Personal Genome Diagnostics
  244. Pfizer
  245. PharmaMar
  246. Phoenix Molecular Designs 
  247. Pierre Fabre
  248. Plexpress
  249. Pharmaceutical Product Development 
  250. Precision for Medicine
  251. PrimeraDx
  252. Progenika Biopharma
  253. Prognomix
  254. ProMedDx
  255. Promega
  256. Prometheus
  257. Provista Diagnostics
  258. Psomagen
  259. Psynova Neurotech
  260. Puma Biotechnology
  261. Q2 Solutions
  262. QED Therapeutics
  263. QIAGEN
  264. QualTek
  265. Quanterix Corporation
  266. Quest Diagnostics
  267. Randox Laboratories
  268. RareCyte
  269. R-Biopharm
  270. Regulus Therapeutics
  271. Renalytix AI
  272. ResearchDx
  273. Resolution Bioscience
  274. Resonance Health
  275. ResourcePath
  276. RiboMed Biotechnologies
  277. Ridge Diagnostics
  278. Riken Genesis
  279. Roche
  280. SAGA Diagnostics
  281. Saladax Biomedical
  282. Seegene
  283. Sheba Medical Center
  284. Shionogi
  285. Shuwen Biotech
  286. Siemens Healthineers
  287. Simcere Diagnostics
  288. Singulex
  289. Sirius Genomics
  290. SkylineDx
  291. SomaLogic
  292. SOPHiA GENETICS
  293. Source BioScience
  294. Spectrum Pharmaceuticals
  295. SRL Diagnostics
  296. Sundance Diagnostics
  297. Sysmex Inostics
  298. Takeda Pharmaceutical
  299. TcLand Expression
  300. Tempus
  301. Tepnel Pharma Services
  302. The Intelligent Tissue Group
  303. Theradex Oncology
  304. TheragenEtex Bio Institute
  305. Theranosis Life Sciences
  306. Theranostics Health
  307. Thermo Fisher Scientific
  308. TIB Molbiol
  309. Tosoh Bioscience
  310. Transgenomic
  311. Translational Research in Oncology
  312. TrimGen
  313. Tymora Analytical Operations
  314. uBiome
  315. UC San Diego Medical Center
  316. UgenTec
  317. UmanDiagnostics
  318. Unilabs
  319. Vertex Pharmaceuticals
  320. Vivia Biotech
  321. Vortex Biosciences
  322. Wave Life Sciences
  323. WuXi NextCODE 

Segmentation

The USD 800+ million (by 2030) financial opportunity within the companion diagnostics development services market has been analysed across the following segments:

  • Type of Service Offered
    • Feasibility Studies
    • Assay Development
    • Analytical Validation
    • Clinical Validation
  • Type of Assay Technique Used
    • in situ hybridization / Immunohistochemistry 
    • Next Generation Sequencing
    • Polymerase Chain Reaction
    • Others
  • Key geographical regions 
    • North America
    • Europe
    • Asia Pacific 

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 4,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com